Driving innovation

in inflammation and fibrosis

LATEST NEWS

Laurent Pharmaceuticals Starts Phase 3 Study with Once-a-Day Oral COVID-19 Antiviral Treatment Candidate in Hospitalized Moderate-to-Severe Patients

15 February 2022
Read More

Laurent Pharmaceuticals extends COVID-19 Phase 2 study with oral antiviral LAU-7b that has showed 100% reduction in the risk of progression onto mechanical ventilation and death

15 December 2021
Read More

About us

Laurent Pharma is a late stage clinical biotech company focusing on developing treatments for complex conditions caused by an unbalanced immune-inflammatory response.

more about us

Science

Targeting cell membrane lipid composition and fluidity as a new paradigm for regulating host defense and the inflammation process.

more on science

Pipeline

Laurent Pharma has completed two Phase 2 clinical studies with LAU-7b, a first-in-class proresolving drug candidate, in cystic fibrosis and COVID-19.

more on pipeline

LAU-7b is an oral drug candidate that showed potential to regulate membrane lipids and exert antiviral, inflammation-controlling, and antifibrotic properties.    

more on LAU-7b

News & Events

Laurent Pharma to participate to BIO International Convention,
June 13-16, 2022 – San Diego, CA
read more
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
read more
Laurent Pharma to participate to BiotechGate, February 7-9, 2022
read more